Pacer Advisors
LXRX icon

Pacer Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Pacer Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-5,387
Closed -$57K – 832
2018
Q3 		$57K Buy
+5,387
New +$61.7K ﹤0.01% 1138
2018
Q1 		– Sell
-1,825
Closed -$18K – 1090
2017
Q4 		$18K Buy
+1,825
New +$19K ﹤0.01% 1104

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
SGA
Sector Gamma AS Oslo, Norway $461M AUM 33.26% 1-Year Est. Return

Pacer Advisors's LXRX Position: Q4 2018 in Review

Pacer Advisors sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2018, closing a stake of 5,387 shares — an estimated $57K sold.

Pacer Advisors first reported a position in LXRX in Q4 2017 and held it in 2 quarters. The position peaked at $57K in Q3 2018. 122 funds tracked by Wall St. Rank hold LXRX as of Q4 2018.

  • Pacer Advisors reported no remaining Lexicon Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Pacer Advisors sold 5,387 Lexicon Pharmaceuticals shares in Q4 2018, an estimated $57K.
  • Pacer Advisors first reported a position in Lexicon Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • Pacer Advisors's Lexicon Pharmaceuticals position peaked at $57K in Q3 2018.
  • 122 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2018.

Based on Pacer Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.